Table 1.
Baseline characteristics, clinical outcomes, and changes to echocardiographic data with mavacamten treatment in 50 patients with obstructive hypertrophic cardiomyopathy.
| Baseline characteristics | |||
|---|---|---|---|
| N | Mean (±SD) or % (N) | P | |
| Age, years | 50 | 63.5 (±13.5) | – |
| Gender,% Female | 50 | 64.0% (32) | – |
| Body mass index, kg/m2 | 50 | 28.5 (±5.4) | – |
| Beta-blocker or calcium channel blocker therapy | 50 | 82.0% (41) | – |
| Beta-blocker therapy | 50 | 68.0% (34) | – |
| Calcium-channel blocker therapy | 50 | 16.0% (8) | – |
| Both medication classes | 50 | 2.0% (1) | – |
| Clinical outcomes with mavacamten treatment | |||
| N | Mean (±SD) or % (N) | P | |
| Time in Mavacamten REMS, weeks | 45 | 35.9 (±17.5) | – |
| Mavacamten temporarily held,% | 50 | 10.0% (5) | – |
| Mavacamten stopped,% | 50 | 6.0% (3) | – |
| New atrial fibrillation,% | 50 | 4.0% (2) | – |
| New ventricular tachycardia,% | 50 | 2.0% (1) | – |
| Death, MCS, or transplant,% | 50 | 6.0% (3) | – |
| Baseline, % (N) | Post-mavacamten, % (N) | P * | |
| NYHA symptom classification | 49 | 43 | <0.001 |
| I - no limitations of activity | 0% (0) | 44.2% (19) | |
| II - slight limitations of activity | 30.6% (15) | 51.2% (22) | |
| III - marked limitations of activity | 69.4% (34) | 4.6% (2) | |
| IV - symptoms at rest | 0% (0) | 0% (0) | |
| Mavacamten dose at follow-up | 47 | 45 | – |
| 2.5 mg | – | 20.0% (9) | – |
| 5 mg | – | 37.8% (17) | – |
| 10 mg | – | 28.9% (13) | – |
| 15 mg | – | 13.3% (6) | – |
| Change in echocardiographic data with mavacamten treatment | |||
| N | Mean absolute delta (95% CI)* | P ** | |
| LVOTr, mmHg | 37 | −33.1 (−45.3, −21.0) | <0.001 |
| LVOTv, mmHg | 32 | −50.1 (−68.5, −31.7) | <0.001 |
| LVEF | 42 | −3.1 (−5.4, −0.83) | 0.0088 |
| LV interventricular septum, cm | 42 | −0.22 (−0.30, −0.13) | <0.001 |
| E/e’ | 19 | −4.0 (−9.7, 1.7) | 0.15 |
| Lateral e’, cm/s | 18 | −0.53 (−1.9, 0.87) | 0.43 |
| Medial e’, cm/s | 21 | −0.88 (−1.7, −0.087) | 0.032 |
| RVSP, mmHg | 23 | −2.5 (−5.6, 0.67) | 0.12 |
| Baseline, % (N) | Post-mavacamten,% (N) | P * | |
|---|---|---|---|
| MR Severity | 47 | 39 | <0.001 |
| None/Trace | 14.9% (7) | 33.3% (13) | |
| Mild | 21.3% (10) | 51.3% (20) | |
| Moderate | 44.7% (21) | 12.8% (5) | |
| Moderately-Severe | 10.6% (5) | 2.6% (1) | |
| Severe | 8.5% (4) | 0% (0) |
LV, left ventricle; LVEF, left ventricular ejection fraction; LVOTv, left ventricular outflow tract obstructive gradient with Valsalva maneuver; LVOTr, left ventricular outflow tract obstructive gradient at rest; MCS, mechanical circulatory support; MR, mitral regurgitation; NYHA, New York Heart Association; RVSP, right ventricular systolic pressure; SD, standard deviation.
*
McNemar-Bowker test used for calculation of P-value.
**
Paired sample t-test used for calculation of P-value and 95% confidence intervals.